ClinicalTrials.gg
Not yet recruitingNCT07824960Panc 004Updated Sep 17, 2026

Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma

A Phase 1/2 interventional study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma and Metastatic Pancreatic Carcinoma, sponsored by University of Virginia. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by University of Virginia · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 298 open to participants now, 471 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Planned enrollment
858th of 1,574
31 · median 37
Started
2026
with 83 others
Phase 1/2
222 of 1,851
42 open now
Primary completion
2029-04
later than 391 of 470 live
Registered
1,838th of 1,851
by date

Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 858th largest by planned enrollment of the 1,574 interventional ones that give a count, is one of 84 that started in 2026, is one of 222 in phase 1/2, reaches primary completion later than 391 of the 470 other live ones, and was the 1,838th registered.

Pancreatic Neoplasms

3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

298 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

293 more — sign in →

All 298 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,851 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to find out if taking two oral study drugs (avutometinib and defactinib) are safe for patients with pancreatic ductal adenocarcinoma (PDAC). Researchers also want to see if the drugs can slow down tumor growth and shrink tumors for possible surgery. These drugs are approved by the FDA to treat a certain kind of ovarian cancer. This study has two parts:

  • Part A is for patients whose cancer has spread to other parts of the body.
  • Part B is for patients whose cancer has not spread, but who cannot have surgery.

Participants will take both drugs as told by their doctor with their regular cancer medicine. Participants will also give blood samples throughout the study. These samples will help researchers learn about how participants respond to treatment and about their pancreatic cancer.

Read the detailed description

Participants in part A will take the study drugs in 28-day cycles for up to 6 cycles with their chemotherapy. Participants whose cancer is not getting worse (known as disease control) may continue the study drugs in combination with maintenance chemotherapy until their disease worsens or negative side effects are noted.

Participants in part B will take the study drugs in 28-day cycles for up to 6 cycles with their chemotherapy. After cycle 4 and cycle 6, participants will have their disease re-assessed with consideration for surgery. Participants whose cancer is not getting worse (disease control) but are ineligible for surgery may continue the study drugs in combination with maintenance chemotherapy until their disease worsens or negative side effects are noted.

03

Conditions studied

  • Pancreatic Cancer
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Metastatic Pancreatic Carcinoma
  • Locally Advanced Pancreatic Cancer

Keywords

  • avutometinib
  • defactinib
  • PDAC
  • pancreatic cancer
  • dual RAF/MEK inhibitor
  • RAF inhibitor
  • MEK inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form.
  2. Individuals ≥ 18 years of age.
  3. Stated willingness to comply with all study procedures and availability for the duration of the study.
  4. Ability to take oral medication and be willing to adhere to the study intervention regimen.
  5. Ability to receive mFOLFIRINOX.
  6. (ECOG) performance status of 0-1.
  7. Adenocarcinoma of the pancreas, confirmed by histology or cytology.

    1. Part A: pancreatic cancer
    2. Part B: Borderline resectable or locally advanced PDAC not eligible for primary surgical resection per institutional standards and following a multidisciplinary discussion at local tumor board
  8. No prior systemic or localized treatment for PDAC.
  9. Radiographically of at least one site by computed tomography (CT) or magnetic resonance (MR) imaging, as defined by (RECIST) 1.1.
  10. Individuals must have adequate organ function defined by the following laboratory parameters:

    (ANC): ≥ 1500/mm3 : ≥100,000/mm3 : ≥9 g/dL Serum Creatinine: ≤ 1.5 x or rate of ≥ 50 mL/min as calculated by the Cockcroft-Gault formula : ≤ 1.5 x ULN (except in patients with Gilbert's disease, where bilirubin to 3x ULN is allowed).

    and ALT: ≤ 2.5 x ULN or ≤ 5 x ULN for patients with liver metastasis : ≤ 1.5 x ULN in the absence of anticoagulation or therapeutic levels in the presence of anticoagulation Creatine phosphokinase (CPK): ≤ 2.5 x ULN

  11. Baseline interval (QTc) interval ≤ 480 millisecond (ms) ( v5.0, Grade 0-1) using Fridericia's QT correction formula.

    • Patients with a left bundle branch block (LBBB) > 480 ms will need their QTc calculated by Bazett (QTc = QT(measured) - 0.5 × QRS(LBBB)).

Exclusion criteria

Exclusion Criteria:

  1. Patients with pancreatic neuroendocrine tumors (PNET), islet cell tumors, mucinous cystic, acinar or squamous (≥ 50%) histology are excluded.
  2. Prior treatment for pancreatic ductal adenocarcinoma.
  3. Presence of distant (Part B only).
  4. Presence of symptomatic ascites or the need for paracentesis within 2 weeks prior to registration.
  5. Major surgery within 4 weeks (excluding placement of vascular access) of registration.
  6. Patients with a prior or concurrent within past 5 years whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the regimen. Examples of malignancies that may be permitted include non-melanoma skin cancer, localized prostate cancer treated with curative intent or under active surveillance, localized thyroid cancer (papillary or follicular), non-muscle invasive low-grade bladder cancer, resected gastrointestinal stromal tumor, stage I testicular cancer post orchiectomy, WHO (World Health Organization) grade 1 meningioma.
  7. Prior treatment with either inhibitors of the RAS/MAPK pathway [e.g., MEK inhibitors] or inhibitors of FAK within the last 6 months.
  8. Patients on treatment with warfarin within 5 days of registration. Patients on warfarin for deep vein thrombosis or pulmonary embolism can be converted to low-molecular-weight heparin or direct oral anticoagulants (DOACs).
  9. Participants requiring medications or supplements with potential for drug-drug interactions, specifically strong or CYP2C9 inhibitors or inducers (Table 7). Participants must be off these medications for 7 days prior to the first dose of study intervention(s). These substances should also be avoided during the course of therapy.
  10. Patients with known UGT1A1 deficiency based on genetic analysis of the UGT1A1 gene.
  11. Receipt of (not limited to the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG) within 30 days of registration. Seasonal influenza vaccines for injection are generally killed virus vaccines and are permitted. However, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not permitted.
  12. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
  13. Active (HIV) infection, unless patient is on effective anti-retroviral therapy and was shown to have a negative viral load within 6 months of registration.
  14. Active Virus (HBV) or (HCV) infection, unless patient is on antiviral therapy and was shown to have a negative viral load test within 6 months of registration.
  15. Active skin disorder that requires current systemic therapy.
  16. Concurrent ocular disorders:

    • Patients with history of glaucoma or history of retinal vein occlusion (RVO).
    • Patients with history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO.
    • Patients with active or chronic, visually significant corneal disorders, other active ocular conditions requiring ongoing therapy that prevent adequate monitoring of drug-induced keratopathy. Examples of visually significant corneal disorders include corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions. Visually significant corneal disorders do NOT include dry eyes, blepharitis, and uncomplicated corneal erosions.
  17. Patients with history of interstitial lung disease (ILD) or pulmonary fibrosis.
  18. Patients with history of severe obstructive pulmonary disease on long-term, home oxygen.
  19. Patients with congestive heart failure III/ IV cardiac disease ( [NYHA]), myocardial infarction within the last 6 months, unstable arrhythmias or unstable angina.
  20. Patients receiving or myelosuppressive medications that, in the opinion of the investigator, would increase the risk of serious neutropenic complications. Subjects receiving replacement therapy of ≤10 mg of prednisone (or the equivalent hydrocortisone dose) per day are eligible.
  21. History of prior allogeneic stem cell or solid organ transplantation.
  22. Patients with impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease.
  23. Patients with pre-existing peripheral neuropathy of Grade ≥2 (severe symptoms limiting self-care ADL (activity of daily living)).
  24. Patients with a history of allergy or known to any of the study treatments or any of their as outlined in the respective package insert.
  25. Individuals with who do not agree to use highly effective method of as described in Lifestyle Considerations (sections 5.4.2 and 5.4.3).
  26. Patients who are pregnant or breastfeeding.
  27. Treatment with another investigational drug during the study participation.
  28. Any other medical condition, related to the underlying disease (e.g., cardiac, gastrointestinal, pulmonary, psychiatric, neurological) that in the opinion of the investigator would place the patient at unacceptably high risk for toxicity.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant avutometinib + defactinib with standard of care chemotherapy

    Avutometinib and defactinib will be taken for 3 weeks, followed by a 1-week rest period in each 4 week cycle.

    Drug: Avutometinib (VS-6766) + Defactinib (VS-6063)

Interventions

  • DrugAvutometinib (VS-6766) + Defactinib (VS-6063)

    Drug page: RO5126766Studies of RO5126766RO5126766 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive avutometinib and defactinib in combination with mFOLFIRINOX (standard of care chemotherapy) in 28-day cycles for up to 6 cycles.

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicities (DLTs) - Part A

    For each participant, we will determine DLTs during first cycle of neoadjuvant therapy

    Time frame: 1 cycle (28 days)

  2. Objective response (OR) - Part B

    PR (partial response) or CR (complete response) per RECIST criteria

    Time frame: through 6 cycles (each cycle is 28 days)

Secondary outcomes

  1. TRAEs (Treatment-related adverse events)

    Cumulative incidence of adverse events as defined by CTCAE v5 tabulating frequency, proportion, and severity

    Time frame: Up to 30 days after completion of study treatment (average of 6 months)

  2. (Part B only): Surgical resection rate

    We will determine the number of participants eligible for surgical resection out the total number of study participants.

    Time frame: after all participants complete up to 6 cycles (each cycle is 28 days)

  3. EFS (event free-survival)

    disease progression, disease recurrence after surgery, or death

    Time frame: through study completion (an average of a year)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2029, 30 months later.

Of 94 non-industry phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 95. This study's planned 30 months is below that.

Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 36 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 17, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2030
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07824960
Collaborators
Verastem, Inc.
Responsible party
Matthew Reilley (Associate Professor; Principal Investigator, University of Virginia) — Principal investigator
First posted
Sep 17, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Apr 2030 (estimated)
Last update
Sep 17, 2026

Study contacts

Amanda Neider
Contact
ALN4K@uvahealth.org
434-566-6768
Kristen Harris
Contact
KAH2GV@uvahealth.org
(434) 297-5724
Matthew Reilley, MD
principal investigator · University of Virginia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RO5126766

Start the discussion